GlaxoSmithKline (GSK) Gets a Buy from Bernstein
Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.
GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'
GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...
devdiscourse6d
GlaxoSmithKline's Profit Surge: A Testament to Resilience
GlaxoSmithKline Pharmaceuticals reported a significant increase in net profit to Rs 229 crore for the third quarter ending ...
Goldman Sachs Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.80.
GlaxoSmithKline share price extends post-Q3 results rally. Jumps 36% in two days
GlaxoSmithKline share price has surged more than 36% in two sessions after the announcement of Q3 results. The stock has ...
USA Today14d
Arizona says GlaxoSmithKline's greed endangered kids with asthma
The lawsuit claims GlaxoSmithKline replaced Flovent with an identical generic version, hurting patients whose insurance wouldn't cover it and costing taxpayers money. Arizona Attorney General Kris ...
pharmaphorum4d
FDA clears GSK's Priorix, first new MMR vaccine in 50 years
With vaccine hesitancy leading to a rise in measles cases, the FDA's approval of GlaxoSmithKline's venerable vaccine Priorix for sale in the US looks timely. Priorix was first launched in Europe ...